The Expression Profile of mRNA and tRNA Genes in Splenocytes and Neutrophils after In Vivo Delivery of Antitumor Short Hairpin RNA of Indoleamine 2,3-Dioxygenase

Ming-Shyan Huang 1,2, Ya-Ling Hsu 3,4,5, I-Jeng Yeh 6,7, Kuan-Ting Liu 6,8 and Meng-Chi Yen 6,7,*

1 Department of Internal Medicine, E-DA Cancer Hospital, Kaohsiung 840, Taiwan; shyan310@gmail.com
2 School of Medicine, I-Shou University, Kaohsiung 840, Taiwan
3 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; hsuyl326@gmail.com
4 Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan
5 Center for Biomarkers and Biotech Drugs, Kaohsiung Medical University, Kaohsiung 807, Taiwan
6 Department of Emergency Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan; ijengyeh@hotmail.com (I.-J.Y.); kuantingliu7@gmail.com (K.-T.L.)
7 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
8 School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan
*
Correspondence: yohoco@gmail.com; Tel.: +886-7-312-1101 (ext. 2015)

Received: 29 July 2020; Accepted: 11 September 2020; Published: 13 September 2020

Abstract: RNA-based therapeutics are considered as novel treatments for human diseases. Our previous study demonstrated that treatment with short-hairpin RNA against Ido1 (IDO shRNA) suppresses tumor growth, detects Th1-bias immune responses, and elevates expression of tryptophan transfer RNA (tRNA^Trp) in total splenocytes. In addition, depletion of Ly6g^+ neutrophils attenuates the effect of IDO shRNA. The aim of this study was to investigate the regulatory network and the expression profile of tRNAs and other non-coding RNAs in IDO shRNA-treated spleens. The total splenocytes and magnetic bead-enriched splenic neutrophils were collected from the lung tumor bearing mice, which were treated with IDO shRNA or scramble IDO shRNA, and the collected cells were subsequently subjected to RNA sequencing. The gene ontology analysis revealed the different enrichment pathways in total splenocytes and splenic neutrophils. Furthermore, the expression of tRNA genes was identified and validated. Six isoacceptors of tRNA, with different expression patterns between total splenocytes and splenic neutrophils, were observed. In summary, our findings not only revealed novel biological processes in IDO shRNA-treated total splenocytes and splenic neutrophils, but the identified tRNAs and other non-coding RNAs may contribute to developing a novel biomarker gene set for evaluating the clinical efficiency of RNA-based cancer immunotherapies.

Keywords: non-coding RNA; transfer RNA (tRNA); RNA sequencing; short-hairpin RNA (shRNA); indoleamine 2,3-dioxygenase1 (IDO1); neutrophil; animal tumor model; biomarker

1. Introduction

RNA-based therapeutics serve as potential treatments for various human diseases. For example, mRNA vaccines, which encode specific antigens, can induce specific immune responses against disease. The effect of multiple mRNA vaccines against infectious diseases and cancers have been evaluated in both animal models and humans [1–3]. Silencing disease-related genes has been demonstrated...
as a strategy to treat various diseases. Antisense oligonucleotide drugs and small interfering RNA (siRNA)-based drugs are approved to treat spinal muscular atrophy, Duchenne muscular dystrophy, and hereditary transthyretin-mediated amyloidosis [4,5]. Moreover, targeting the immune inhibitory genes via siRNA or short-hairpin RNA (shRNA) can induce immune responses against cancers [6,7]. However, the molecular level mechanisms in siRNA/shRNA-targeted immune cells, and the biomarkers for evaluating the therapeutic effect, are not well known.

Indoleamine 2,3-dioxygenase 1 (IDO1) is a tryptophan-degrading enzyme, and an important immune suppressive gene in dendritic cells of tumor-draining lymphoid organs [8,9]. As the kynurenine, which is degraded from tryptophan by IDO1 enzyme activity and downstream derivative metabolites of kynurenine plays, an important role in immune suppression, multiple types of IDO1 inhibitors are developed for cancer treatments [10]. Our previous studies revealed that in vivo delivery of IDO shRNA suppresses tumor growth in several murine tumor models, including the LLC1 lung tumor model [11–13]. The effect of IDO shRNA treatment is different from treatment with D-1-methyl-tryptophan (D-1MT), an inhibitor of IDO1. In the LLC1 tumor model, depletion of Ly6g+ neutrophils in the spleen abolishes the therapeutic effect of IDO shRNA treatment, but does not affect the therapeutic effect of D-1MT [11]. This may suggest that Ly6g+ neutrophils play a critical role in IDO shRNA-mediated antitumor.

Expansion of immature neutrophils can be observed in circulating blood and the spleen of tumor-bearing mice [14]. These immature neutrophils, as well as splenic immature neutrophils, are considered to be immune-suppressive and tumor-supporting neutrophils [15–17]. The current evidence reveals that transforming growth factor-β (TGF-β) is a major regulator for immune-suppressive neutrophils, which can be switched to antitumor neutrophils via blockage of TGF-β [18]. However, our previous study revealed that TGF-β may not be a key regulator of splenic neutrophils in IDO shRNA-mediated antitumor responses [11]. Since the tumor-specific cytotoxic T cell can be activated by IDO shRNA in spleen [12,13], the signaling pathways of splenic immune cells are worthy of being further investigated.

Furthermore, the expression of tryptophan tRNA (tRNA^{Trp}) was increased in IDO shRNA-treated total splenocytes [11], but the function and regulation of tRNA^{Trp} was unknown. The physiology functions of many non-coding RNAs were identified, and some of these non-coding RNAs can be used as therapeutic targets, and prognostic and diagnostic biomarkers for several types of cancers [19,20]. We wondered whether the expression of tRNAs, and other non-coding RNAs in immune cells, was associated with IDO shRNA treatment and its antitumor effect. This study aimed to investigate the novel signaling pathways, and the expression profile of protein-coding RNAs and non-coding RNAs, in IDO shRNA-treated total splenocytes and splenic neutrophils in lung tumor-bearing mice.

2. Results

2.1. The Effect of IDO1 shRNA on LLC1 Tumor-Bearing Mice

Our previous studies demonstrated that IDO shRNA treatment delayed tumor growth and resulted in an increasing number of tumor-infiltrating neutrophils [11–13]. However, the mechanism for its antitumor effect was not fully understood, especially the role of splenic neutrophils. To investigate the potential regulatory mechanism in splenic neutrophils and total splenocytes, LLC1-tumor-bearing mice were injected with IDO shRNA or scramble IDO shRNA (Scr IDOsh), and then the total splenocytes and magnetic bead-enriched neutrophils were collected, and then subjected to RNA sequencing (Figure 1a). Similar to our previous studies, the mean tumor volume in IDO shRNA treated-groups was smaller than that in Scr IDO1shRNA-treated groups at day 16, post injection of LLC1 tumor cells (Figure 1b). The immunohistochemistry staining analysis confirmed that the IDO shRNA treatment increased the number of Ly6g+ tumor-infiltrating neutrophils (Figure 1c,d). The result showed the effect of IDO shRNA treatment in the present study was similar to our previous studies.
was further examined in culture medium, which were cultured total splenocytes for 24 h (Figure 2c–h). The present results were comparable to those in our previous study [11]. Moreover, the expression of splenic neutrophils were measured via RNA sequencing and quantitative PCR (QPCR). The protein expression of these inflammatory molecules was further examined in culture medium, which were cultured total splenocytes for 24 h (Figure 2c–h). The present results were comparable to those in our previous study [11]. Moreover, the expression of splenic neutrophils were measured via RNA sequencing and QPCR (Figure 2i, j). The protein expression analysis of splenic neutrophils was not performed because insufficient neutrophils were collected. The expression patterns of most genes identified by RNA sequencing were similar to those of the QPCR analysis in splenic neutrophils.

2.2. The Expression Patterns of Inflammatory Molecules in Total Splenocytes and Splenic Neutrophils

Various genes with differential expression were identified via the results of RNA sequencing. The results of extracted RNA quantity assessment and the mapping summary are shown in Supplementary Figure S1. The result of RNA sequencing showed that the expression of IDO in total splenocytes was not significantly affected by IDO shRNA treatment, and was similar to our previous studies [11]. In addition, the expression of several cytokines, including interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-4 (IL-4), and IL-10, had been determined in the IDO shRNA-treated LLC1-tumor bearing mice in our previous study [11]. To validate the results of RNA sequencing, the inflammatory molecules expression of total splenocytes, determined via RNA sequencing and quantitative PCR (QPCR), are shown in Figure 2a, b, respectively. The protein expression of these inflammatory molecules was further examined in culture medium, which were cultured total splenocytes for 24 h (Figure 2c–h). The present results were comparable to those in our previous study [11]. Moreover, the expression of splenic neutrophils were measured via RNA sequencing and QPCR (Figure 2i, j). The protein expression analysis of splenic neutrophils was not performed because insufficient neutrophils were collected. The expression patterns of most genes identified by RNA sequencing were similar to those of the QPCR analysis in splenic neutrophils.
Figure 2. The expression of inflammatory molecules. (a) The expression of inflammatory molecules of total splenocytes, determined by RNA sequencing and (b) by QPCR. To detect the secreted protein levels, splenocytes were collected at 16 days after LLC1 injection. After 24-h culture, these molecules were detected by magnetic fluorescence microsphere immunoassay (MAGPIX) analysis. The expression of (c) IFN-γ, (d) IL-10, (e) TNF-α, (f) IL-1α, (g) CCL5, and (h) S100A9 was shown. (i) The expression of inflammatory molecules of splenic neutrophils determined by RNA sequencing and (j) by QPCR. *, **, and *** A statistically significant difference when compared with scramble IDO shRNA group (* p < 0.05; ** p < 0.01; *** p < 0.001). n = 3–4 in each experiment, except to RNA sequencing data. IFN-γ, interferon-γ; IL-10, interleukin-10; TNF-α, tumor necrosis factor-α; TGF-β, tumor transforming growth factor-β; CCL5, CC chemokine ligand 5; S100A9, S100 calcium-binding protein A9; Arg1, arginase 1.

2.3. IDO shRNA-Mediated Pathways in Total Splenocytes and Splenic Neutrophils

A total of 334 and 237 protein coding genes, with differential expression, were identified from the results of RNA sequencing of total splenocytes and splenic neutrophils, respectively. The full list of these genes is shown in Supplementary Tables S1 and S2. The gene ontology analysis, including immune system process, biological process, molecular function, and cellular component, was performed via ClueGo and CluePedia [21]. The graphical network is shown in Figure 3a,b and the detailed list is shown in Tables 1 and 2. The results revealed that the significantly enriched biological processes in IDO shRNA-treated total spleen were different from those in IDO shRNA-treated splenic neutrophils. Compared to Scr IDOshRNA-treated total splenocytes, various biological processes, such as porphyrin-containing compound biosynthetic process, detoxification, erythrocyte differentiation,
positive regulation of vasculature development, and response to inorganic substance, were enriched in IDO shRNA-treated splenocytes. By contrast, the enriched biological processes, including killing of cells of other organisms, mitotic sister chromatid segregation, myeloid cell development, etc., were observed in IDO shRNA-treated neutrophils.

**Figure 3.** The IDO shRNA-mediated network of biological processes. The Scr IDO shRNA-treated splenocytes or neutrophils, and the identified genes, with differential expression in IDO shRNA-treated cells, were selected, and then the gene ontology analysis was performed via ClueGo and CluePedia. (a) The enriched biological processes in IDO shRNA-treated splenocytes (p value < 0.001). (b) The enriched biological processes in IDO shRNA-treated splenic neutrophils (p value < 0.01).
Table 1. The gene ontology enrichment analysis of total splenocytes.

| Gene Ontology Term                                      | Count | p Value $^1$ |
|---------------------------------------------------------|-------|--------------|
| GO: 0006778~porphyrin-containing compound metabolic process | 13    | $1.77 \times 10^{-12}$ |
| GO: 0006779~porphyrin-containing compound biosynthetic process | 11    | $1.09 \times 10^{-11}$ |
| GO: 0042168~heme metabolic process                      | 10    | $3.48 \times 10^{-09}$ |
| GO: 0098754~detoxification                              | 17    | $3.93 \times 10^{-09}$ |
| GO: 0051186~cofactor metabolic process                  | 28    | $5.38 \times 10^{-09}$ |
| GO: 0048821~erythrocyte development                     | 11    | $6.56 \times 10^{-09}$ |
| GO: 0046501~protoporphyrinogen IX metabolic process     | 7     | $7.39 \times 10^{-09}$ |
| GO: 0010035~response to inorganic substance             | 34    | $1.30 \times 10^{-08}$ |
| GO: 009636~response to toxic substance                  | 33    | $1.82 \times 10^{-08}$ |
| GO: 0030218~erythrocyte differentiation                 | 16    | $2.98 \times 10^{-08}$ |
| GO: 0002262~myeloid cell homeostasis                    | 18    | $4.65 \times 10^{-08}$ |
| GO: 1990748~cellular detoxification                     | 15    | $5.21 \times 10^{-08}$ |
| GO: 0006783~heme biosynthetic process                   | 8     | $8.70 \times 10^{-08}$ |
| GO: 0097237~cellular response to toxic substance        | 21    | $1.13 \times 10^{-07}$ |
| GO: 0055076~transition metal ion homeostasis            | 15    | $2.17 \times 10^{-07}$ |
| GO: 0016209~antioxidant activity                        | 13    | $3.79 \times 10^{-07}$ |
| GO: 0051188~cofactor biosynthetic process               | 17    | $7.02 \times 10^{-07}$ |
| GO: 0004857~enzyme inhibitor activity                   | 11    | $1.97 \times 10^{-06}$ |
| GO: 0004601~peroxidase activity                         | 9     | $4.48 \times 10^{-05}$ |
| GO: 0051187~cofactor catabolic process                  | 9     | $5.89 \times 10^{-05}$ |
| GO: 0046394~carboxylic acid biosynthetic process        | 18    | $1.12 \times 10^{-04}$ |
| GO: 0002444~myeloid leukocyte mediated immunity          | 6     | $1.17 \times 10^{-04}$ |
| GO: 0034755~iron ion transmembrane transport            | 6     | $1.17 \times 10^{-04}$ |
| GO: 0045869~negative regulation of proteolysis          | 21    | $1.56 \times 10^{-04}$ |
| GO: 003099~myeloid cell differentiation                 | 21    | $2.62 \times 10^{-04}$ |
| GO: 0042743~hydrogen peroxide metabolic process         | 8     | $3.37 \times 10^{-04}$ |
| GO: 1904018~positive regulation of vasculature development | 14   | $4.16 \times 10^{-04}$ |
| GO: 0032787~monocarboxylic acid metabolic process       | 26    | $4.61 \times 10^{-04}$ |
| GO: 0070541~response to metal ion                       | 23    | $8.59 \times 10^{-06}$ |
| GO: 0004857~enzyme inhibitor activity                   | 22    | $3.90 \times 10^{-05}$ |
| GO: 0017144~drug metabolic process                      | 27    | $4.02 \times 10^{-05}$ |
| GO: 0004601~peroxidase activity                         | 9     | $4.48 \times 10^{-05}$ |
| GO: 0051187~cofactor catabolic process                  | 9     | $5.89 \times 10^{-05}$ |
| GO: 0046394~carboxylic acid biosynthetic process        | 18    | $1.12 \times 10^{-04}$ |
| GO: 0015669~gas transport                              | 6     | $1.17 \times 10^{-04}$ |
| GO: 0042743~hydrogen peroxide metabolic process         | 8     | $3.37 \times 10^{-04}$ |
| GO: 0000070~mitotic sister chromatid segregation        | 9     | $1.26 \times 10^{-03}$ |
| GO: 0061515~myeloid cell development                    | 7     | $1.33 \times 10^{-03}$ |
| GO: 0000086~G2/M transition of mitotic cell cycle       | 8     | $1.44 \times 10^{-03}$ |
| GO: 0002446~neutrophil mediated immunity                | 5     | $2.01 \times 10^{-03}$ |
| GO: 0051702~interaction with symbiont                   | 7     | $2.70 \times 10^{-03}$ |
| GO: 0030218~erythrocyte differentiation                 | 8     | $3.12 \times 10^{-03}$ |
| GO: 0008519~ammonium transmembrane transporter activity | 3     | $3.68 \times 10^{-03}$ |
| GO: 1902850~microtubule cytoskeleton organization involved in mitosis | 8 | $4.26 \times 10^{-03}$ |

$^1$ p value was corrected with Bonferroni step down, according to ClueGO. The gene ontology term value < 0.001 is shown in this Table.

Table 2. The Gene ontology enrichment analysis of splenic neutrophils.

| Gene Ontology Term                                      | Count | p Value $^1$ |
|---------------------------------------------------------|-------|--------------|
| GO: 0031640~killing of cells of other organism          | 7     | $2.77 \times 10^{-04}$ |
| GO: 0051873~killing by host of symbiont cells           | 5     | $3.41 \times 10^{-04}$ |
| GO: 0015669~gas transport                              | 6     | $1.17 \times 10^{-04}$ |
| GO: 0034755~iron ion transmembrane transport            | 6     | $1.17 \times 10^{-04}$ |
| GO: 0042743~hydrogen peroxide metabolic process         | 8     | $3.37 \times 10^{-04}$ |
| GO: 1904018~positive regulation of vasculature development | 14   | $4.16 \times 10^{-04}$ |
| GO: 0002444~myeloid leukocyte mediated immunity          | 14    | $4.16 \times 10^{-04}$ |
| GO: 0000070~mitotic sister chromatid segregation        | 9     | $1.26 \times 10^{-03}$ |
| GO: 0061515~myeloid cell development                    | 7     | $1.33 \times 10^{-03}$ |
| GO: 0000086~G2/M transition of mitotic cell cycle       | 8     | $1.44 \times 10^{-03}$ |
| GO: 0002446~neutrophil mediated immunity                | 5     | $2.01 \times 10^{-03}$ |
| GO: 0051702~interaction with symbiont                   | 7     | $2.70 \times 10^{-03}$ |
| GO: 0030218~erythrocyte differentiation                 | 8     | $3.12 \times 10^{-03}$ |
| GO: 0008519~ammonium transmembrane transporter activity | 3     | $3.68 \times 10^{-03}$ |
| GO: 1902850~microtubule cytoskeleton organization involved in mitosis | 8 | $4.26 \times 10^{-03}$ |
Table 2. Cont.

| Gene Ontology Term                                      | Count | p Value $^1$               |
|--------------------------------------------------------|-------|---------------------------|
| GO:0002262~myeloid cell homeostasis                    | 9     | $4.30 \times 10^{-03}$   |
| GO:0140014~mitotic nuclear division                    | 11    | $4.38 \times 10^{-03}$   |
| GO:0006335~DNA replication-dependent nucleosome assembly | 4     | $5.15 \times 10^{-03}$   |
| GO:0002888~positive regulation of myeloid leukocyte mediated immunity | 5     | $6.90 \times 10^{-03}$   |
| GO:0030168~platelet activation                         | 6     | $8.14 \times 10^{-03}$   |
| GO:0000050~urea cycle                                  | 3     | $8.24 \times 10^{-03}$   |

$^1$ p value was corrected with Bonferroni step down, according to ClueGO. The gene ontology term value < 0.01 is shown in this Table.

2.4. The Expression Profile of Transfer RNA (tRNA)

Apart from the protein coding genes, the transcription of tRNA genes was also determined via RNA sequencing. A total of 237 tRNA genes, which were recognized by codons of 19 types of amino acids and selenocysteine, were identified. In Figure 3a, the heatmap shows the expression patterns of each identified tRNA gene (Figure 4a). However, the tRNA of tryptophan (tRNA-Trp) was not identified via RNA sequencing. To confirm the results of RNA sequencing and determine the expression of tRNA-Trp, the expression of tRNA-GluCTC, tRNA-LeuCAA, tRNA-IleTAT, and tRNA-TrpCCA was recorded, via QPCR. Compared to the results of RNA sequencing (Figure 4b), the QPCR-determined expression of the other tRNA genes was generally similar (Figure 4c,d). Similarly to our previous study, a higher expression of tRNA-Trp was detected in IDO shRNA-treated splenocytes and neutrophils, when compared to Scr IDO shRNA-treated splenocytes and neutrophils. In addition, 56 tRNA genes in total splenocytes, and 67 tRNA in splenic neutrophils genes, with a mean expression ratio of >2 or <0.5, were observed. The 30 identical tRNA genes in both cells are shown in Table 3.

![Figure 4](image-url)

**Figure 4.** The expression of tRNA genes. (a) The heatmap shows the expression of each tRNA gene. Each column indicates a specific tRNA gene. The relative color scheme is based on minimum-maximum values (RPKM), per column. (b) The expression of some tRNA genes identified via RNA sequencing in total splenocytes and splenic neutrophils. (c) The expression of some tRNA genes identified via QPCR in total splenocytes, and (d) in splenic neutrophils. n = 3–4 in QPCR analysis. * A statistically significant difference when compared with the Scr IDO shRNA group (* p < 0.05).
The transcription of tRNA was regulated by RNA polymerase III. The results showed that only a part of the tRNA genes expression was significantly changed after IDO shRNA treatment; we supposed that the RNA polymerase III machinery was not altered. The expression of RNA polymerase III machinery, including the subunit of RNA polymerase III, the transcription factor for polymerase III B (TFIIB), and TFIIC, was not significantly altered by IDO shRNA treatment in both cells (Figure 5a). Moreover, aminoacyl-tRNA synthetases are a group of enzymes which pair tRNAs with their cognate amino acids [22]. However, IDO shRNA treatment did not affect the transcriptional change of these aminoacyl-tRNA synthetases genes in RNA sequencing data (Figure 5b). Therefore, this may imply that the transcription of these tRNA genes is regulated via other mechanisms, but not common tRNA regulatory mechanisms.
Figure 5. The potential regulatory genes of tRNA transcription. (a) The expression of RNA polymerase III machinery, including the subunits of RNA polymerase III (RNA polIII), transcription factor for polymerase III B (TFIIIB), and TFIIIC. (b) The expression of aminoacyl-tRNA synthetase genes. The official gene symbol of each aminoacyl-tRNA synthetase gene is shown on the label of x-axis in this figure.

2.6. The Fragments Derived from tRNAs

The fragments derived from tRNAs (tRFs) are a type of small non-coding RNA, which derive from tRNA and are considered as biomarkers for human diseases or regulators for biological functions [23,24]. Since the transcription of specific tRNA genes was affected by IDO shRNA treatment, the tRFs derived from these tRNA were supposed to be affected as well. The potential mouse tRFs were evaluated via the tRFdb database [25], and the 5′-tRFs and 3′-tRFs, related to the tRNA identified in Table 3, are shown in Tables 4 and 5, respectively. As the QPCR data indicated that expression of tRNA-Trp-CCA-4-1 in the IDO shRNA treated group was higher than that in the Scr IDO shRNA treated group, the 3′-tRF of tRNA-Trp-CCA-4-1 was listed.

Table 4. The list of 5′-tRFs.

| GtRNAdb Gene Symbol | tRF ID  | Type  | Sequence                                      |
|---------------------|---------|-------|-----------------------------------------------|
| tRNA-Gly-GCC-1-1    | 5002a   | trf-5 | GCATGGGTGTTCTAGTGTTAGA                        |
|                     | 5002b   |       | GCATGGGTGTTCTAGTGTTAGAATTCTCGCC               |
| tRNA-Gly-GCC-2-1    |         |       |                                               |
| tRNA-Gly-GCC-2-6    |         |       |                                               |
| tRNA-Gly-GCC-2-7    | 5004a   | trf-5 | GCATGGGTGTTCTAGTGTTAGA                        |
|                     | 5004b   |       | GCATGGGTGTTCTAGTGTTAGAATTCTCGCC               |
| tRNA-Lys-CTT-3-1    |         |       |                                               |
| tRNA-Lys-CTT-3-1    | 5006a   | trf-5 | GCCCGGCTAGCTAGTGTTAGA                        |
|                     | 5006b   |       | GCCCGGCTAGCTAGTGTTAGAGC                      |
| tRNA-Val-CAC-2-1    |         |       |                                               |
| tRNA-Val-CAC-2-2    |         |       |                                               |
| tRNA-Val-CAC-2-3    | 5019a   | trf-5 | GTTCCTAGTGTTAGTGAG                           |
|                     | 5019b   |       | GTTCCTAGTGTTAGTGTTATCAG                      |
| tRNA-Glu-TTC-1-3    | 5020a   | trf-5 | TCCCCCATGGTGCTAGCGAG                         |
|                     | 5020b   |       | TCCCCCATGGTGCTAGCGGAG                        |
Table 5. The list of 3′-tRFs.

| GtRNAdb Gene Symbol | tRF ID  | Type | Sequence                        |
|---------------------|---------|------|---------------------------------|
| tRNA-Gly-GCC-1-1    | 3043a   |      | TTCCCGGCCCATGCACCA              |
|                     | 3043b   | trf-3| TCGATTCCCGGCCCATGCACCA          |
| tRNA-Gly-GCC-2-1    |         |      |                                 |
| tRNA-Gly-GCC-2-2    |         |      |                                 |
| tRNA-Gly-GCC-2-3    | 3042a   |      | TTCCCGGCCAATGCACCA              |
|                     | 3042b   | trf-3| TCGATTCCCGGCCAATGCACCA          |
| tRNA-Gly-GCC-2-6    |         |      |                                 |
| tRNA-Gly-GCC-2-7    |         |      |                                 |
| tRNA-Gly-GCC-2-8    |         |      |                                 |
| tRNA-Lys-CTT-3-1    | 3031a   |      | AGCCCCACGTGGGCGCCA              |
|                     | 3031b   | trf-3| TCGAGCCCCACGTGGGCGCCA           |
| tRNA-Val-CAC-2-1    |         |      |                                 |
| tRNA-Val-CAC-2-2    | 3009a   |      | ACGGGGGGAAACACCA                |
|                     | 3009b   | trf-3| TCGAAACCGGGCAGAAACCA            |
| tRNA-Val-CAC-2-3    |         |      |                                 |
| tRNA-Val-CAC-2-4    |         |      |                                 |
| tRNA-Glu-TTC-1-3    | 3029a   |      | CTCCCGGTGTGGGAACCA              |
|                     | 3029b   | trf-3| TCGACTCCCGGTGGGAACCA            |
| tRNA-Trp-CCA-4-1    | 3002a   |      | ATCACGTGGGTGGGTACCA             |
|                     | 3002b   | trf-3| TCAATACGTGGGTGGGTACCA           |

2.7. The Other Types of Non-Coding RNAs

Except for the tRFs, the other types of non-coding RNAs, such as RIKEN cDNA genes, small nucleolar RNA genes, and microRNA (miRNA) genes were identified by RNA sequencing. The RNA sequencing respectively identified 29 and 17 miRNA genes, in total splenocytes and splenic neutrophils, according to the criteria expression ratio > 2 or < 0.5, and RPKM > 0.1. However, the function of these non-coding RNAs in IDO shRNA-affected immune cells was not understood. To investigate the potential interactions between miRNAs and protein coding genes, the protein-coding genes-targeted miRNAs were predicted, via the miRNet website [26]. According to the, 334 and 237 protein coding genes, respectively, identified from total splenocytes and splenic neutrophils, 252 and 177 miRNAs were predicted to target the protein-coding genes with differential gene expression. In Figure 6a,b, the Venn diagrams show that four miRNAs (mmu-mir-5107-5p, mmu-mir-1955-3p, mmu-mir-10a-5p, mmu-mir-5126) and one miRNA (mmu-mir-3066-5p) were observed in both the predicted miRNA list and the result of RNA sequencing. The full list of miRNAs and other non-coding RNA genes are shown in Supplementary Tables S3 and S4.

Figure 6. Venn diagrams indicating the shared miRNA genes between miRNet-predicted miRNAs and RNA sequencing-identified miRNAs. (a) Total splenocytes. (b) Splenic neutrophils.
3. Discussion

Our previous study demonstrated that the depletion of Ly6g⁺ neutrophils abolished the antitumor effect of IDO shRNA treatment in a murine lung tumor model [11]. Thus, we were interested in investigating the role of splenic neutrophils during the treatment of IDO shRNA. Since the tumor growth was significantly inhibited by IDO shRNA at day 16 post tumor cells injection, the total splenocytes were collected at day 16. According to our original experiment design, the total splenocytes and the splenic neutrophils should be collected from the same mice. However, the collected cell number was insufficient to perform RNA sequencing. Therefore, the splenic neutrophils were collected from other mice at day 18 post tumor cells injection. Except for the sample for RNA sequencing, the other samples of total splenocytes and splenic neutrophils for other experiments (Figures 2 and 4) were collected from the same mice at day 16. According to the results of QPCR analysis, the RNA expression patterns of splenic neutrophils collected at day 16 (QPCR) were similar to those at day 18 (RNA sequencing) (Figure 2).

The function of neutrophils can be polarized to antitumorigenic phenotype (N1) or protumorigenic phenotype (N2), and influences immune responses in the tumor environment [27]. Therefore, induction of N1 polarization should be beneficial for improving the efficiency of tumor treatments. A recent study has demonstrated that primary human neutrophils, toward N1 and N2 phenotypes, are feasible in vitro [28]. As neutrophils depletion attenuated the antitumor effect of IDO shRNA [11], we hypothesized that IDO shRNA treatment may affect the polarization of neutrophils in spleen. High expression of intercellular adhesion molecule 1 and TNF-α, and low expression of Arg1 are characteristics of N1 antitumorigenic neutrophils [18,29]. However, our results revealed that the splenic neutrophils did not express classic markers of N1 and N2 phenotypes at this time point (Figure 2). Based on the gene ontology analysis, the positive regulation of neutrophils or myeloid leukocytes-mediated immunity, was observed (Table 2). Therefore, we still supposed that the splenic neutrophils play roles in activating antitumor immune responses, through other mechanisms in the IDO shRNA-treated spleen.

The present study did not investigate each type of immune cell in the IDO shRNA-treated spleen, but the transcriptome of total splenocytes. In Table 1, various enriched pathways involved in regulating the porphyrin-related pathways are shown. Tryptophan (Trp) degrading enzymes, IDO and tryptophan 2,3-dioxygenase (TDO), were considered to affect the porphyrin-related pathways [30]; however, the expression of IDO and TDO was not significantly changed in total splenocytes and splenic neutrophils. This may imply the downstream metabolic pathway of tryptophan was still affected after IDO shRNA treatment. In addition, some enriched pathways in total splenocytes were involved in the process of reactive oxygen species (ROS). Recent evidence indicated that ROS are not only a trigger for activating cell death signaling, but an important regulator for controlling T cell signaling and metabolism [31]. Thus, the role of ROS-related pathways in IDO shRNA-mediated antitumor immune responses needs to be further investigated.

Transfer RNAs are products of RNA polymerase III. We expected that the RNA polymerase III machinery should not be affected by IDO shRNA treatment, because the results of RNA sequencing revealed that the expression of tRNA genes was not globally affected (Figure 5a). Previous studies showed that several types of aminocacyl-tRNA synthetases, including tryptophanyl tRNA synthetase (WRS), lysyl-tRNA synthetase (KRS), and glycyl-tRNA synthetase (GRS) were involved in regulation of immune responses [32,33]. For example, secretion of full-length WRS results in induction of antiviral immunity in immune cells [34]. In immune thrombocytopenia, increased WRS expression in CD4⁺ and CD8⁺ T cells may enhance survival of autoreactive T cells [35]. As the elevated expression of tRNA_{TRP} was detected in total splenocytes and splenic neutrophils, we supposed that the WRS expression may be associated with the expression of tRNA_{TRP}, and that the expression of other types of aminocacyl-tRNA synthetases may be affected by IDO shRNA treatment. However, the expression of all aminocacyl-tRNA synthetases was not significantly changed (expression ration <2 or >0.5, Figure 5b). Thus, the results
suggested that the tRNAs with differential expression were not directly associated with the expression of aminocacyl-tRNA synthetases.

The tRNA-derived fragments, which were cleavage from precursor tRNAs and mature tRNAs, play roles in physiological processes [23,24]. Four types of tRFs, including 5′-tRFs, 3′-tRFs, 1′-tRFs, and 2′-tRFs, have been identified [36]. After stimulation of anti-CD3 and anti-CD28 antibodies, the tRNA fragments in the primary T cell-secreted extracellular vesicles play a role in the inhibition of T cell activation [37]. Moreover, six types of tRNA fragments, including GlyGCC, GluCTC, GluTTC, GluCCTG, LysCIT, and LysTTT, can be mapped to the extracellular vesicles-secreted primary mouse dendritic cells. In addition, lipopolysaccharide or 1α,25-dihydroxyvitamin D3 stimulation did not affect the expression of the six tRNA isoacceptors [38]. The present study showed the six isoacceptors of tRNA (GlyTCC, GlyGCC, AspGTC, GluTTC, ValCIT, and LysCIT), with different expression profiles between total splenocytes and splenic neutrophils. The known tRNA fragments of the six tRNA isoacceptors and TrpCAA are listed in Tables 4 and 5. We will try to evaluate the function of these tRNA fragments in immune cells and secreted extracellular vesicles in the future.

The other types of small non-coding RNAs were also identified. However, the roles of most non-coding RNA in immune responses was not understood. In addition, the potential miRNA-mediated network was not validated by experimental evidence. Recent studies have determined the physiological roles of the small non-coding immune cells [39,40]. However, the functions of the tRNAs and non-coding RNAs identified in this study were mainly unknown. Due to the antitumor effect of IDO shRNA, we supposed that these non-coding RNAs may be associated with positive regulation of antitumor immunity, and served as biomarkers for evaluating the therapeutic effect of shRNA-based cancer treatment. Our previous studies demonstrated that shRNA against Ido1, Foxa3, Thbs1, and Clec4a2 can enhance the antitumor effect of Her2/neu DNA vaccine in the murine tumor model [12,41–43]. We will try to investigate whether these non-coding RNA can serve as convincing biomarkers for shRNA-mediated therapies.

In summary, the present study revealed that IDO shRNA treatment resulted in positive regulation of neutrophil immunity, and ROS-related pathways in total splenocytes. Furthermore, various non-coding RNAs were identified and may be a novel biomarker gene set for evaluating the shRNA-based antitumor treatment via skin administration or intramuscular injection. RNA technology-mediated cancer immunotherapies have been applied in preclinical studies and clinical trials [6,44]. Even though the route of administration for RNA technology-mediated cancer immunotherapies is different from our present study, our finding provides a novel biomarker gene set for these RNA-based cancer therapeutics.

4. Materials and Methods

4.1. Cell Culture

LLC1 (LL/2) was purchased from the Bioresource Collection and Research Center (Hsinchu, Taiwan). LLC1 was cultured by Dulbecco’s modified Eagle’s medium (Lonza, Walkersville, MD, USA) containing 10% fetal bovine serum and penicillin/streptomycin (100 U/0.1 mg/mL) (Life Technologies, Grand Island, NY, USA).

4.2. Plasmid Preparation

IDO shRNA (IDOsh) plasmid (specifically targeting Ido1) and Scramble IDO shRNA (Scr IDOsh) were described in our previous study [12]. The DNA plasmid was prepared via Plasmid DNA MaxiPrep Kit (Norgene, St. Catharines, ON, Canada) according to the manufacturer’s instructions. Both DNA plasmids were dissolved in physiological saline at a concentration of 0.5 μg/μL.

4.3. Animal Tumor Model and Therapeutic Effect

All the animal experiments in this study were approved by the Animal Care and Use Committee at the Kaohsiung Medical University. All mice were held by the Center for Laboratory Animals of
Kaohsiung Medical University, which was accredited by Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). To establish a subcutaneous tumor, $2 \times 10^5$ cells, which were suspended in 200 µL serum-free DMEM, were injected subcutaneously into six- to eight-week old female inbred C57BL/6JNarl mice (National Laboratory Animal Center, Taiwan). The mice were received with intramuscular injection (50 µg of IDO shRNA or scramble IDO shRNA in 100 µL saline) at day 7 and 14 post LLC1 injection. Tumor size was measured by using calipers every 3–4 days, and tumor volume was calculated according to the formula: (shortest diameter)$^2 \times$ (longest diameter) $\times$ 0.5236. For RNA sequencing, 4 mice were used in each group. For the following experiments, including immunohistochemical analysis, QPCR analysis, and soluble factors analysis, 7 mice were used in each group. All mice were injected with LLC1 cells and then developed subcutaneous tumors.

4.4. Immunohistochemical Analysis of Ly6g$^+$ Cells

LLC1 tumor samples were collected at day 16, post tumor injection. Four tumor samples were obtained from IDO shRNA and Scr IDO shRNA-treated tumor-bearing mice, respectively. The formalin-fixed, paraffin-embedded section of tumor lesions were then analyzed using immunohistochemistry. The Ly6g$^+$ cells were detected by anti-Ly6g antibody (Taiclone, Taiwan, Cat.: tcea21879, 1:300 dilution). The immunoreactivity was visualized using a diaminobenzidine (DAB) substrate (DAKO, Denmark), subsequently counterstained with hematoxylin. Mouse spleen samples were used for positive control, and Rabbit IgG (Abcam, Cambridge, UK, Cat.: ab172730, diluted to 1.2 µg/mL) were used for negative control. The images were scanned via 3DHISTECH Panoramic Desk II DW. Images were chosen from three random fields by CaseViewer software (3DHISTECH), and then the images were determined by Image J 1.52 version (NIH, Bethesda, MD, USA) with a plugin named “IHC Profiler” [45].

4.5. Detection of Soluble Factors

The soluble factors were measured via Magnetic Luminex® Assays (Mouse Premixed Multi-Analyte Kit, R&D Systems, Minneapolis, MN, USA) on a Luminex MagPix® instrument (Luminex). Briefly, $2 \times 10^6$ of total spleen cells were cultured in a 24-well plate with 1000 µL RPMI 1640, and supplied with 10% FBS and penicillin/streptomycin for 24 h. After removing cells, the culture medium was collected and stored at $-80$ °C until performing experiments. The data were calculated using Milliplex Analyst 5.1 Software (Viagene Tech, Carlisle, MA, USA) according to a five-parameter logistic curve fit curve method.

4.6. Collection of Total Splenocytes and Enrichment of Neutrophils

The spleen was collected from IDO shRNA- and Scr IDO shRNA-treated mice at day 16 and 18, post injection of LLC1 cells. Total splenocytes were minced with scissors, digested in spleen dissociation medium (Stem Cell Technologies, Vancouver, BC, Canada), and then removed red blood cells via ammonium chloride solution (Stem Cell Technologies, Vancouver, BC, Canada) using the recommended protocols. To further enrich mouse neutrophils from total spleen cells, an EasySep™ Mouse Neutrophil Enrichment Kit (Stem Cell Technologies, Vancouver, BC, Canada) was used according to manufacturer’s instructions. The purity of sorted cells was routinely more than 80%.

4.7. RNA Sequencing

The total splenocytes and neutrophils were collected from two IDO shRNA- or Scr IDO shRNA-treated mice. The pooled cells were homogenized in TRIzol reagent (Thermo Fisher Scientific, Inc., Carlsbad, CA, USA) and then total RNA was extracted. RNA sequencing was technically provided by the Center of Genomic Medicine, National Cheng Kung University. In brief, the library preparation was performed with the NEBNext® Ultra™ Directional RNA Library Prep Kit for Illumina (NEW ENGLAND BioLabs, Cat.: #E7420). Subsequently, the qualified libraries were analyzed by FRAGMENT
ANALYZER™ Automated CE System (Advanced Analytical Technologies, Inc., Ankeny, IA, USA) and quantified by Qubit Fluorometer (ThermoFisher). The libraries were sequenced with the Illumina sequencing platform. Mapping and whole transcriptome analysis was performed via TopHat [46] and Bowtie2 [47] software package, mapped to the Mouse genome (mm10), respectively. The sequence of mapped tRNA genes was further examined by GtRNAdb [25] and Genomic tRNA database [48].

4.8. Gene ontology Analysis

The criteria of differential gene expressions was set at gene expression ratio of >2 or <0.5, and reads per kilobase million (RPKM) >0.1. For performing the gene ontology analysis and drawing the graphical network, Cytoscape software version 3.7.1 was used, with APPs “ClueGO (version 2.5.7)” [21,49]. Briefly, the gene ontology in ClueGo was set as the “functional analysis” mode, visual style “groups”, ontologies/pathways “GO-BiologicalProcess”, “GO-CellularComponent”, “GO-MolecularFunction”, and “GO-ImmuneSystemProcess”. The pathways with p value < 0.01 (splenic neutrophils) and p value < 0.001 (total splenocytes) were shown, respectively. The network specificity was set at “Go Tree Interval” from 3 min level to 4 max level.

4.9. Quantitative Real-Time Polymerase Chain Reaction (QPCR)

Total RNA was extracted with a Total RNA Purification Kit (Norgene, St. Catharines, ON, Canada). For determining mRNA and tRNA, complementary DNA (cDNA) was performed using a Prime-Script RT Reagent Kit (Clontech, Kusatsu, Shiga, Japan). All real-time PCR were run on a QuantStudio 5 Real-Time PCR system (Applied Biosystems) using the PrimeScript RT reagent kit (TaKaRa BIO, Shiga, Japan) at the program of 95 °C for 20 s, and then 40 cycles of 95 °C for 3 s, and 60 °C for 30 s. The relative mRNA expression was normalized to the expression of internal control hypoxanthine phosphoribosyltransferase (HPRT) by 2^−ΔΔCt (cycle time) method [50]. For determining the expression of tRNA genes, the primers were designed according to the tRNA sequences adapted from tRFdb [25]. U6 small nuclear RNA served as the internal control. The calculation of relative tRNA expression was the same as that of relative mRNA expression. A total of 3-4 replicates were used per sample in the QPCR assay. The primer sequences were listed in Table 6.

| Target Gene                        | Primer Sequence                  |
|-----------------------------------|----------------------------------|
| Hypoxanthine phosphoribosyltransferase (HPRT) | Forward: 5'-GTTTGATACAGGCCAGACTTTGTG-3'  |
| IFN-γ                             | Reverse: 5'-GATTCAACTTGGCTACATTTAGGC-3'  |
| TNF-α                             | Forward: 5'-CACCTAGCTACTACATTTAGGC-3'  |
| IL-10                             | Reverse: 5'-GCCCAAAGGATGAGAAGTT-3'  |
| TGF-β                             | Forward: 5'-TCGGCTTACAGGATTTAAA-3'  |
| Arginase 1                        | Reverse: 5'-CGTCAAAAAGACAGGCCACTCA-3'  |
| tRNA-Glu-CTC-1-6                   | Forward: 5'-CAGAGGATGGAAGATCAG-3'  |
| tRNA-Leu-CAA-2-1                   | Reverse: 5'-CAGATAGGAGGATGACC-3'  |
| tRNA-Arg-CAA-2-1                   | Forward: 5'-TGCTCACAGGCGAGATGCT-3'  |
| tRNA-Trp-CAA-4-1                   | Reverse: 5'-TGACCCGGACGTTACTTGT-3'  |
| U6                                | Forward: 5'-CGTACAGGAAAGATTAGCATGCC-3'  |
4.10. Statistical Analysis

All of the numerical data and graphs were generated by GraphPad Prism v8.4.3 (GraphPad Software, San Diego, CA, USA). Data represent mean ± SD. Unpaired two-tailed Student’s t-test was used for analysis of the difference between two groups, and a p value < 0.05 was considered to indicate a statistically significant difference.

5. Conclusions

RNA-based therapeutics provide novel and important strategies to treat cancer. The present study performed the transcriptomic analysis for total spleen and splenic neutrophils. Except for the enriched biological pathways, the tRNAs and other non-coding RNAs with significant different expression were identified. This knowledge may be beneficial for understanding regulatory mechanisms of IDO shRNA or other shRNA-based antitumor treatments in immune cells, especially in splenic neutrophils. These data may contribute to developing a novel biomarker gene set for evaluating the clinical efficiency of cancer immunotherapies.

Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/21/18/6703/s1. Figure S1: Read Quality Distribution with mean quality (in Phred Score) in x-axis and number of reads in y-axis for samples individually (a) Total splenocytes IDOsh day16. (b) Total splenocytes Scr IDOsh day16. (c) Splenic neutrophils IDOsh day18. (d) Splenic neutrophils Scr IDOsh day18. Phred Score meaning: Quality scores range from 4 to about 60, with higher values corresponding to higher quality. The quality scores are logarithmically linked to error probabilities. (e) The mapping summary of this study; Table S1. The list of protein-coding genes in total splenocytes with significant changes; Table S2. The list of protein-coding genes in splenic neutrophils with significant changes; Table S3. The list of non-coding RNA genes in total splenocytes with significant changes; Table S4. The list of non-coding RNA genes in splenic neutrophils with significant changes.

Author Contributions: Conceptualization, M.-S.H., Y.-L.H., and M.-C.Y.; preparing the materials and performing the experiments, Y.-L.H., and M.-C.Y.; analyzing the sequencing data via bioinformatic methods, M.-S.H., Y.-H.L., I.-J.Y., K.-T.L., J.-H.S., M.-C.Y.; writing—original draft preparation, M.-C.Y.; Writing—review and editing, M.-S.H., Y.-L.H., I.-J.Y., and K.-T.L.; funding acquisition, M.-S.H., and M.-C.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by grants from the E-DA Cancer Hospital (EDCHP-109013), the Ministry of Science and Technology (MOST 106-2320-B-037-029-MY3, MOST 107-2320-B-037-011-MY3), and the Kaohsiung Medical University Hospital (KMUH107-7R81, KMUH108-8R72).

Acknowledgments: We gratefully acknowledge the technical support for RNA sequencing analysis by Center of Genomic Medicine, National Cheng Kung University.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Pardi, N.; Hogan, M.J.; Porter, F.W.; Weissman, D. mRNA vaccines—A new era in vaccinology. *Nat. Rev. Drug Discov.* **2018**, *17*, 261–279. [CrossRef] [PubMed]
2. Zhang, C.; Maruggi, G.; Shan, H.; Li, J. Advances in mRNA Vaccines for Infectious Diseases. *Front. Immunol.* **2019**, *10*, 594. [CrossRef] [PubMed]
3. Dolgin, E. Unlocking the potential of vaccines built on messenger RNA. *Nature* **2019**, *574*, S10–S12. [CrossRef] [PubMed]
4. DeWeerdt, S. RNA therapies explained. *Nature* **2019**, *574*, S2–S3. [CrossRef]
5. Conceicao, I. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system. *Clin. Auton. Res.* **2019**, *29* (Suppl. 1), 11–17. [CrossRef] [PubMed]
6. Lin, Y.X.; Wang, Y.; Blake, S.; Yu, M.; Mei, L.; Wang, H.; Shi, J. RNA Nanotechnology-Mediated Cancer Immunotherapy. *Theranostics* **2020**, *10*, 281–299. [CrossRef]
7. Yen, M.C.; Chou, S.K.; Kan, J.Y.; Kuo, P.L.; Hou, M.F.; Hsu, Y.L. New Insight on Solute Carrier Family 27 Member 6 (SLC27A6) in Tumoral and Non-Tumoral Breast Cells. *Int. J. Med. Sci.* **2019**, *16*, 366–375. [CrossRef]
8. Munn, D.H.; Sharma, M.D.; Hou, D.; Baban, B.; Lee, J.R.; Antonio, S.J.; Messina, J.L.; Chandler, P.; Koni, P.A.; Mellor, A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. *J. Clin. Investig.* **2004**, *114*, 280–290. [CrossRef]

9. Sharma, M.D.; Baban, B.; Chandler, P.; Hou, D.Y.; Singh, N.; Yagita, H.; Azuma, M.; Blazar, B.R.; Mellor, A.L.; Munn, D.H. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. *J. Clin. Investig.* **2007**, *117*, 2570–2582. [CrossRef]

10. Zhai, L.; Bell, A.; Ladomersky, E.; Lauing, K.L.; Bollu, L.; Sosman, J.A.; Zhang, B.; Wu, J.D.; Miller, S.D.; Meeks, J.; et al. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies. *Front. Immunol.* **2020**, *11*, 1185. [CrossRef]

11. Liu, K.T.; Liu, Y.H.; Liu, H.L.; Chong, I.W.; Yen, M.C.; Kuo, P.L. Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3-Dioxygenase Mediated-antitumor Efficiency. *Mol. Ther. Nucleic Acids* **2016**, *5*, e397. [CrossRef] [PubMed]

12. Yen, M.C.; Lin, C.C.; Chen, Y.L.; Huang, S.S.; Yang, H.J.; Chang, C.P.; Lei, H.Y.; Lai, M.D. A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA. *Clin. Cancer Res.* **2009**, *15*, 641–649. [CrossRef] [PubMed]

13. Huang, T.T.; Yen, M.C.; Lin, C.C.; Weng, T.Y.; Chen, Y.L.; Lin, C.M.; Lai, M.D. Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. *Cancer Sci.* **2011**, *102*, 2214–2220. [CrossRef] [PubMed]

14. Evrard, M.; Kwok, I.W.H.; Chong, S.Z.; Teng, K.W.W.; Becht, E.; Chen, J.; Siew, J.L.; Penny, H.L.; Ching, G.C.; Devi, S.; et al. Developmental Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. *Immunity* **2018**, *48*, 364–379.e8. [CrossRef]

15. Youn, J.I.; Collazo, M.; Shalova, I.N.; Biswas, S.K.; Gabrilovich, D.I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. *J. Leukoc. Biol.* **2012**, *91*, 167–181. [CrossRef]

16. Bronte, V.; Brandau, S.; Chen, S.H.; Colombo, M.P.; Frey, A.B.; Greten, T.F.; Mandruzzato, S.; Murray, P.J.; Ochoa, A.; Ostrand-Rosenberg, S.; et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. *Nat. Commun.* **2016**, *7*, 12150. [CrossRef]

17. Ouzounova, M.; Lee, E.; Piranioglu, R.; El Andaloussi, A.; Kolhe, R.; Demirici, M.F.; Marasco, D.; Asm, I.; Cheddi, A.; Hassan, K.A.; et al. Monocytic and granulocytic myeloid-derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. *Nat. Commun.* **2017**, *8*, 14979. [CrossRef]

18. Fridlender, Z.G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G.S.; Albelda, S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. *Cancer Cell* **2009**, *16*, 183–194. [CrossRef]

19. Slack, F.J.; Chinnaiyan, A.M. The Role of Non-coding RNAs in Oncology. *Cell* **2019**, *179*, 1033–1055. [CrossRef]

20. Uchida, S.; Adams, J.C. Physiological roles of non-coding RNAs. *Am. J. Physiol. Cell Physiol.* **2019**, *317*, C1–C2. [CrossRef]

21. Bindea, G.; Mlecnik, B.; Hackl, H.; Charoentong, P.; Tosolini, M.; Kirilovsky, A.; Fridman, W.H.; Pages, F.; Trajanoski, Z.; Galon, J. ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics* **2009**, *25*, 1091–1093. [CrossRef] [PubMed]

22. Rubio Gomez, M.A.; Ibba, M. Aminoacyl-tRNA synthetases. *RNA* **2020**, *26*, 910–936. [PubMed]

23. Keam, S.P.; Hutvagner, G. tRNA-Derived Fragments (tRFs): Emerging New Roles for an Ancient RNA in the Regulation of Gene Expression. *Life* **2015**, *5*, 1638–1651. [CrossRef] [PubMed]

24. Schimmel, P. The emerging complexity of the tRNA world: Mammalian tRNAs beyond protein synthesis. *Nat. Rev. Mol. Cell. Biol.* **2018**, *19*, 45–58. [CrossRef] [PubMed]

25. Kumar, P.; Mudunuri, S.B.; Anaya, J.; Dutta, A. tRFdb: A database for transfer RNA fragments. *Nucleic Acids Res.* **2015**, *43*, D141–D145. [CrossRef]

26. Fan, Y.; Xia, J. miRNet-Functional Analysis and Visual Exploration of miRNA-Target Interactions in a Network Context. *Methods Mol. Biol.* **2018**, *1819*, 215–233.

27. Giese, M.A.; Hind, L.E.; Huttenlocher, A. Neutrophil plasticity in the tumor microenvironment. *Blood* **2019**, *133*, 2159–2167. [CrossRef]

28. Ohms, M.; Moller, S.; Laskay, T. An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes in vitro. *Front. Immunol.* **2020**, *11*, 532. [CrossRef]
29. Fridlender, Z.G.; Sun, J.; Mishalian, I.; Singhal, S.; Cheng, G.; Kapoor, V.; Horng, W.; Fridlender, G.; Bayuh, R.; Worthen, G.S.; et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. *PLoS ONE* 2012, 7, e31524. [CrossRef]

30. Badawy, A.A. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. *Int. J. Tryptophan Res.* 2017, 10, 1178646917691938. [CrossRef]

31. Franchina, D.G.; Dostert, C.; Brenner, D. Reactive Oxygen Species: Involvement in T Cell Signaling and Metabolism. *Trends Immunol.* 2018, 39, 489–502. [CrossRef] [PubMed]

32. Nie, A.; Sun, B.; Fu, Z.; Yu, D. Roles of aminoacyl-tRNA synthetases in immune regulation and immune diseases. *Cell Death Dis.* 2019, 10, 901. [CrossRef] [PubMed]

33. Jin, M. Unique roles of tryptophanyl-tRNA synthetase in immune control and its therapeutic implications. *Exp. Mol. Med.* 2019, 51, 1–10. [CrossRef] [PubMed]

34. Lee, H.C.; Lee, E.S.; Uddin, M.B.; Kim, T.H.; Kim, J.H.; Chathuranga, K.; Chathuranga, W.A.G.; Jin, M.; Kim, S.; Kim, C.J.; et al. Released Tryptophanyl-tRNA Synthetase Stimulates Innate Immune Responses against Viral Infection. *J. Virol.* 2019, 93. [CrossRef] [PubMed]

35. Wang, C.Y.; Shi, Y.; Min, Y.N.; Zhu, X.J.; Guo, C.S.; Peng, J.; Dong, X.Y.; Qin, P.; Sun, J.Z.; Hou, M. Decreased IDO activity and increased TTS expression break immune tolerance in patients with immune thrombocytopenia. *J. Clin. Immunol.* 2011, 31, 643–649. [CrossRef]

36. Li, S.; Xu, Z.; Sheng, J. tRNA-Derived Small RNA: A Novel Regulatory Small Non-Coding RNA. *Genes* 2018, 9, 246. [CrossRef] [PubMed]

37. Chiou, N.T.; Kageyama, R.; Ansel, K.M. Selective Export into Extracellular Vesicles and Function of tRNA Fragments during T Cell Activation. *Cell Rep.* 2018, 25, 3356–3370.e4. [CrossRef]

38. Driedonks, T.A.P.; van der Grein, S.G.; Ariyurek, Y.; Buermans, H.P.J.; Jekel, H.; Chow, F.W.N.; Wauben, M.H.M.; Buck, A.H.; ‘t Hoen, P.A.C.; Nolte-’t Hoen, E.N.M. Immune stimuli shape the small non-coding transcriptome of extracellular vesicles released by dendritic cells. *Cell Mol. Life Sci.* 2018, 75, 3857–3875. [CrossRef]

39. Okuyama, K.; Ogata, J.; Yamakawa, N.; Chanda, B.; Kotani, A. Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis. *Int. J. Hematol.* 2014, 99, 553–560. [CrossRef]

40. Gonzalez Plaza, J.J. Small RNAs as Fundamental Players in the Transference of Information during Bacterial Infectious Diseases. *Front. Mol. Biosci.* 2020, 7, 101. [CrossRef]

41. Weng, T.Y.; Li, C.J.; Li, C.Y.; Hung, Y.H.; Yen, M.C.; Chang, Y.W.; Chen, Y.H.; Chen, Y.L.; Hsu, H.P.; Chang, J.Y.; et al. Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8+ Immunity In Vivo. *Mol. Ther. Nucleic Acids* 2017, 9, 419–427. [CrossRef] [PubMed]

42. Weng, T.Y.; Huang, S.S.; Yen, M.C.; Lin, C.C.; Chen, Y.L.; Lin, C.M.; Chen, W.C.; Wang, C.Y.; Chang, J.Y.; Lai, M.D. A novel cancer therapeutic using thrombospondin 1 in dendritic cells. *Mol. Ther.* 2014, 22, 292–302. [CrossRef] [PubMed]

43. Weng, T.Y.; Bukhari, A.B.; Malhotra, R.; De, A. IHC Profiler: An open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. *PLoS ONE* 2014, 9, e96801. [CrossRef]

44. Kim, D.; Pertea, G.; Trapnell, C.; Pimentel, H.; Kelley, R.; Salzberg, S.L. TopHat2: Accurate alignment of transcripts in the presence of insertions, deletions and gene fusions. *Genome Biol.* 2013, 14. [CrossRef]

45. Langmead, B.; Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 2012, 9, 357–359. [CrossRef] [PubMed]

46. Lowe, T.M.; Eddy, S.R. tRNAscan-SE: A program for improved detection of transfer RNA genes in genomic sequence. *Nucleic Acids Res.* 1997, 25, 955–964. [CrossRef]
49. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. *Genome Res.* 2003, 13, 2498–2504. [CrossRef]

50. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. *Methods* 2001, 25, 402–408. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).